Report Overview

The China Antidepressants market size stood at around USD 8.5 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

China has a large depression patient numbers which accounts for nearly 7.3% of the chinese population and is more prominent among the white-collar officers of Shanghai, Beijing, and Guangzhou. The Hospital visits with antidepressant prescriptions reflected 42.6% increase in the past five years. The antidepressants prescription is approximately 1.6 times more for women as compared to men. The most frequent age category for antidepressant prescriptions was 4564 years. Antidepressant prescribing rates continue to increase in China, although the prescribing patterns have changed over the past few years. The wide use of expensive antidepressants and those with weak clinical evidence raises concerns regarding the rational use of antidepressants.



Market Drivers

Growing public awareness about depression, changes in patients attitudes, the expansion of therapeutic indications, and the impact of commercial interests are the primary drivers for the growth of Anti-depressants market in china. In clinical practice, antidepressants are prescribed for many conditions other than depression, such as anxiety, sleeping disorders, psychosis, and neuropathic pain. This has led to concerns that antidepressants are being overprescribed. Also, with accelerated development of china, various social contradictions have become prominent, peoples life pressure has increased, and the incidence of depression has continued to rise. The rapid development of the depression medication market and product declarations have shown a prosperous trend in the Chinese market.